ArticleJournal of medical case reports2025
Successful treatment of large-cell neuroendocrine carcinoma of the prostate with pembrolizumab: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge-cell neuroendocrine carcinoma of the prostate is an extremely rare disease and classified into two subtypes: de novo and treatment-induced large-cell neuroendocrine carcinoma that arises from adenocarcinoma via lineage plasticity in response to long-term hormonal therapy. Although successful outcomes have been reported for some de novo large-cell neuroendocrine carcinoma cases of the prostate, the prognosis of large-cell neuroendocrine carcinoma of the prostate remains poor. CASE PRESENTATION: A 69-year-old East Asian man diagnosed with adenocarcinoma of the prostate had been treated with androgen deprivation therapy and androgen receptor signaling inhibitors for 4.5 years without elevation of prostate-specific antigen levels. He complained of lumbar, abdominal, and perineal pain and was diagnosed as having treatment-induced large-cell neuroendocrine carcinoma of the prostate with cT4N1M0 on clinicopathological examination. Total pelvic exenteration and pelvic lymph node dissection were performed, followed by adjuvant chemoradiotherapy, which resulted in local recurrence. Since comprehensive genomic profiling of the surgical specimen showed it was microsatellite instability-high, pembrolizumab was administered, and complete remission was achieved. The patient has shown no signs of recurrence for more than 2 years after the diagnosis of large-cell neuroendocrine carcinoma of the prostate.
conclusionsPembrolizumab combined with surgical resection, radiotherapy, and systemic chemotherapy may improve the prognosis of patients with treatment-induced large-cell neuroendocrine carcinoma of the prostate, although further accumulation of cases is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.